Are you a researcher or medical professional who can help with research?
If you are a medical professional or researcher who is interested in being involved in research, or have patients who may be potential study participants, please see the research calls below.
An investigation into current practice in psychological aspects of Acquired Brain Injury rehabilitation
Polina Greskova, MSc Applied Neuropsychology student, University of Glasgow
UK survey of adult acquired brain injury rehabilitation professionals
Researchers at the University of Glasgow are conducting a UK-wide anonymous survey exploring current practice in psychological and cognitive aspects of adult acquired brain injury rehabilitation.
The survey looks at real-world rehabilitation practice, including goal-setting, intervention approaches, patient and family involvement, outcome monitoring, use of guidelines, discharge, follow-up and service constraints. The study partly builds on the UK survey conducted by Wilson et al. (2008) and Nowell et al. (2020), aiming to update the picture of contemporary ABI rehabilitation and broaden it across the wider MDT.
They would particularly welcome professionals who have experience supporting adults following encephalitis, especially social workers, medics, OTs, SLTs, case managers, alongside psychologists, neuropsychologists at any career stage. You can take part if you currently work in UK adult ABI rehabilitation, or if you have at least six months’ previous UK experience in this area. Participants can be from any relevant profession and at any career stage, including trainees and assistants.
The anonymous online survey takes approximately 15-20 minutes, depending on your caseload and professional role: https://uofg.qualtrics.com/jfe/form/SV_0c8LT7bV1158PWu?=q
Participants can also choose to enter a prize draw for one of three £30 shopping vouchers and/or receive a brief summary of the findings. Contact details for these options are collected separately from survey responses.
Music Listening after Acquired Brain Injury: Perspectives from clinical practice
Emma Sowden, Postgraduate Researcher, University of Glasgow
This study investigates current uses and perceptions of music listening after acquired brain injury, from the perspective of clinicians who work with this population. The aim is to understand how music listening is currently viewed, recommended or incorporated into care, and where clinicians perceive potential benefits or limitations in clinical practice. Participation involves an online survey, with the option to take part in a one-off online focus group to discuss these themes in more detail. By taking part, you can help contribute to building a picture of the role music listening may play in brain injury rehabilitation and recovery.
For this study, ‘clinician’ refers to healthcare professionals who currently provide assessment, treatment, rehabilitation, or ongoing clinical care for people with acquired brain injury as part of their professional role. This includes, but is not limited to, psychologists, neuropsychologists, music therapists, occupational therapists, physicians, nurses, physiotherapists, speech and language therapists, psychiatrists, neurologists, rehabilitation medicine physicians, and other allied health professionals involved in acquired brain injury care.
Online survey: https://uofg.qualtrics.com/jfe/form/SV_cGUgXzkZbrUNphY
Patients needed for the The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH)
NEW CLNIC SITE OPEN: Rotterdam, The Netherlands
ExTINGUISH Trial is a Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease
What is Inebilizumab?
Inebilizumab is a promising therapeutic monoclonal antibody for the treatment of NMDAR encephalitis. This humanized monoclonal antibody against the B-cell surface antigen CD19 was recently shown to be safe and efficacious in the treatment of neuromyelitis optica spectrum disorder—another antibody-mediated disorder of the central nervous system. Compared to other off label B-cell depleting therapies, such as rituximab, inebilizumab not only depletes CD20+ B-cells, but also CD20- plasma blasts and plasma cells, resulting in robust, broad and sustained suppression of B-cell expression
Patient Criteria
- Patients in the US and Europe (Rotterdam), The Netherlands at least moderately affected by NMDAR encephalitis
- US – aged 12 and up
- EU – will initially recruit from aged 18 and up
Clinicians are encouraged to use the Trial Hotline to discuss their patient: 844-4BRAIN5 (844-427-2465)
Find out more
Call for research centres worldwide to participate in INFECT-HEAD Study
You are invited to join the prospective international collaborative study titled “Defining the uncovered nature of infection-related headaches accompanying various infections: a prospective study (INFECT-HEAD Study).”
Aim of the study:
The aim of this study is to investigate the characteristics, time course, severity, and location of headaches associated with various acute systemic and local infections in adults over 18 years worldwide. In addition to examining phenotypic characteristics, the study will explore the relationship between simple infectious parameters (such as fever and CRP) and headaches. The information gathered will inform the treatment strategies in the future.
Criteria for inclusion:
A maximum of 2 researchers from each centre and 20 case entries per researcher. All patients with headache attributed to infection can be included, including all active infections in inpatients or outpatients.
Lead institution:
SBU Şişli Hamidiye Etfal Education and Research Hospital, İstanbul, Turkey
For more information and to join the study, please contact Assoc Prof Tuba Cerrahoglu Sirin on tubacerrahoglu@hotmail.com